Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Link
https://link.springer.com/content/pdf/10.1007/s10147-020-01693-y.pdf
Reference28 articles.
1. Thompson RH, Ordonez MA, Iasonos A et al (2008) Renal cell carcinoma in young and old patients—is there a difference? J Urol 180(4):1262–1266. https://doi.org/10.1016/j.juro.2008.06.037(discussion 1266, PMID: 18707708 PMCID: PMC2615196)
2. Konishi S, Hatakeyama S, Tanaka T et al (2018) Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis. Med Oncol 36(1):6. https://doi.org/10.1007/s12032-018-1231-3(PMID: 30474747)
3. Harada K, Nozawa M, Uemura M et al (2019) Treatment patterns and outcomes in patients with unresectable or metastatic renal cell carcinoma in Japan. Int J Urol 26(2):202–210. https://doi.org/10.1111/iju.13830(PMID: 30345560)
4. Tsuchiya N (2019) Molecular-targeted therapy in advanced renal cell carcinoma based on pharmacokinetics, pharmacodynamics and pharmacogenetics: a proposed strategy. Int J Urol 26(1):48–56. https://doi.org/10.1111/iju.13805(PMID: 30276868)
5. Konishi S, Hatakeyama S, Numakura K et al (2019) Validation of the IMDC prognostic model in patients with metastatic renal-cell carcinoma treated with first-line axitinib: a multicenter retrospective study. Clin Genitourin Cancer 17(5):e1080–e1089. https://doi.org/10.1016/j.clgc.2019.07.006(PMID: 31416753)
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Safety and efficacy of nivolumab in elderly patients with metastatic clear cell renal cell carcinoma: analysis of the NIVOREN GETUG-AFU 26 study;European Journal of Cancer;2024-02
2. Primary resistance to nivolumab plus ipilimumab therapy in patients with metastatic renal cell carcinoma;Cancer Medicine;2023-07-05
3. Incidence of immune checkpoint inhibitor mediated cardiovascular toxicity: A systematic review and meta‐analysis;European Journal of Clinical Investigation;2022-07-21
4. Severe Immune-Related Adverse Events in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma Are Associated with PDCD1 Polymorphism;Genes;2022-07-05
5. Real-World Experience with Nivolumab in Metastatic Renal Cell Carcinoma Patients Who Have Progressed on Prior Therapies: A Single-Center Study from India;South Asian Journal of Cancer;2022-02-11
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3